Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension

Phase

Condition

Diabetes And Hypertension

High Blood Pressure (Hypertension - Pediatric)

Stress

Treatment

N/A

Clinical Study ID

NCT05545059

2020-KY-126

Ages 18-75
All Genders

Study Summary

Resistant hypertension (RH) accounted for a considerable proportion of patients with hypertension. It has been revealed to impose certain adverse effects on the prognosis of patients with cardiovascular diseases. The antihypertensive effect of sacubitril/valsartan being fully confirmed in previous studies, there were no related randomized controlled trials (RCT) about this potency among Chinese patients with RH. The investigators designed this study to evaluated effects and safety of sacubitril/valsartan versus valsartan on Chinese patients with RH.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Clinical diagnosis of resistant hypertension
≥18 and ≤75 years old at the time of randomization
Must agree to comply with all requirements and sign the informed consent form

Exclusion

Exclusion Criteria:

unwilling to sign informed consent.
Severe renal insufficiency
Research related drug contraindications
secondary hypertension
Cardiovascular event
Persistent arrhythmia, valvular heart disease, and class III-IV heart failure or leftventricular ejection fraction <45%.
Severe liver function impairment (Child-Pugh C), biliary cirrhosis and/or cholestasis
History of angioedema and asthma
Woman of childbearing age who do not take effective contraceptive measures or pregnantor breastfeeding
Allergic to drugs related to the study
Suffering from serious tumor-related diseases, receives tumor-related treatment, orhas a life expectancy of less than 2 years
Planning to join other clinical trials
Anticipated changes in medical conditions
Need to take study-related drugs for reasons other than hypertension
Suffering from other diseases that may prevent the patient from participating fullyperiod of the study
Other any concomitant conditions
Must continuously take any drugs that affect the results

Study Design

September 24, 2022

March 31, 2023

Study Description

Background Resistant hypertension (RH) accounted for a considerable proportion of patients with hypertension. It has been revealed to impose certain adverse effects on the prognosis of patients with cardiovascular diseases. The antihypertensive effect of sacubitril/valsartan being fully confirmed in previous studies, there were no related randomized controlled trials (RCT) about this potency among Chinese patients with RH.

Purpose Describing the design of the Effects of Sacubitril/valsartan Versus Valsartan on Refractory Hypertension (EOSORH) trial.

Methods and analysis This is a monocentric, randomized, parallel-group, controlled trial which will investigate the efficacy and safety of sacubitril/valsartan in the treatment of Chinese patients with RH. A total of 138 patients will be enrolled who are diagnosed with RH according to the Guidelines for Prevention and Treatment of Hypertension in China (2018 revision). After a washout period, subjects will be randomized to sacubitril/valsartan group or valsartan group in a 1:1 ratio. The primary outcome is the change in 24 hours average ambulatory systolic blood pressure (SBP) from baseline to 8 weeks after randomization, comparing the sacubitril/valsartan group with valsartan group. The secondary outcomes including change in 24 hours average ambulatory diastolic blood pressure (DBP), clinic blood pressure and series of cardiac and renal hematologic indicators. Safety endpoints will also be evaluated, covered changes in blood potassium level, renal function, hypotension, etc. Full Analysis Set (FAS), per-protocol set (PPS) and safety set (SS) will be defined. Baseline data will be analyzed by using data from FAS whereas the analysis of primary outcome will be based on FAS and PPS but the conclusions of FAS are dominant.

Ethics and dissemination The research protocol has been approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. This research is designed to investigate the efficacy and safety of sacubitril/valsartan in Chinese RH patients. Findings will be shared by Sun Yat-sen Memorial Hospital, policymakers and the academic community to promote the clinical pharmacal therapy of RH in China.

Discussion The effects of sacubitril/valsartan on hypertension have been widely reported by a series of large RCT in recent years, while its application in RH patients is still elusive. The study will provide a new pharmacal strategy for the treatment of RH.

Connect with a study center

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong 510120
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.